Related Experiment Videos
Neuroleptic malignant syndrome in parkinsonian patients: risk factors
1Department of Neurology and Clinical Research Center, Utano National Hospital, Narutaki, Kyoto, Japan. BXD03644@niftyserve.or.jp
Abstract:
A syndrome resembling the neuroleptic malignant syndrome (NMS) is known to develop occasionally following interruption of dopaminergic medications in patients with Parkinson's disease. However, NMS can develop even without withdrawal of antiparkinsonian drugs. In parkinsonian patients who continually received dopaminergic medications, the development of NMS occurred exclusively in warm seasons, May to August. The development of NMS could occur at any season in association with the cessation of dopaminergic drugs. A female parkinsonian patient showed two episodes of NMS during the premenstrual period. It is suggested that hot weather or dehydration and aggravation of parkinsonism premenstrually constitute risk factors for the development of NMS, in addition to withdrawal of antiparkinsonian drugs.
Insights
Neuroleptic Malignant Syndrome (NMS) can occur in Parkinson's disease patients due to dopaminergic drug withdrawal or even without it. Hot weather and premenstrual factors may increase NMS risk, alongside drug cessation.
Area of Science:
- Neurology
- Pharmacology
Background:
- Neuroleptic Malignant Syndrome (NMS) is a rare but serious condition.
- It is known to occur in patients with Parkinson's disease, often after dopaminergic medication withdrawal.
Purpose of the Study:
- To investigate the specific risk factors and seasonal patterns associated with NMS development in Parkinson's disease patients.
- To explore potential triggers beyond medication withdrawal.
Main Methods:
- Observational analysis of NMS cases in Parkinson's disease patients.
- Correlation of NMS occurrence with medication status, season, and patient-specific factors.
Main Results:
- NMS can occur in Parkinson's patients even without dopaminergic drug withdrawal.
- When dopaminergic drugs were continued, NMS exclusively occurred during warmer months (May-August).
- NMS development could occur in any season if associated with dopaminergic drug cessation.
Conclusions:
- Seasonal factors, such as hot weather and dehydration, may contribute to NMS risk in Parkinson's patients on continuous dopaminergic therapy.
- Premenstrual exacerbation of parkinsonism is a potential risk factor.
- Both dopaminergic drug withdrawal and other factors like season and premenstrual state are critical considerations for NMS in Parkinson's disease.